Investigates IgG N-glycosylation's role in mediating adiposity and tobacco effects on cardiovascular risk, suggesting new targets.
BACKGROUND: Despite interest in the health effects of IgG N-glycosylation, the mediating role of IgG N-glycosylation in the effects of adiposity and tobacco use on cardiovascular diseases (CVDs) has not been systematically studied. OBJECTIVE: This study aimed to investigate the causal effects of adiposity and tobacco use on CVDs and the potential mediating role of 23 traits of IgG N-glycosylation using Mendelian randomization (MR). METHODS: Summary statistics from GWAS were used. Two-sample MR assessed the causal links between adiposity, tobacco use, and CVDs, while two-step MR examined whether IgG N-glycosylation traits mediate these associations. Random-effects inverse-variance weighted analyses, along with MR-Egger, weighted median, simple, and weighted model approaches, were conducted. RESULTS: We observed genetically predicted body mass index (OR = 1.48, 95% CI: 1.40, 1.56), fat mass index (OR = 1.68, 95% CI: 1.37, 2.06), fat-free mass index (OR = 1.55, 95% CI: 1.27, 1.89), lifetime smoking index (OR = 1.75, 95% CI: 1.43, 2.14), and smoking initiation (OR = 1.15, 95% CI: 1.06, 1.25) were positively associated with CVDs. Moreover, IGP5 mediated 5.4% of the effect of BMI on pulmonary embolism, whereas IGP7 mediated 2.8% of the effect of BMI on coronary artery disease. CONCLUSION: Our findings illustrated the causal associations of adiposity and tobacco use with CVDs, with IgG N-glycosylation traits potentially acting as mediators, and thereby highlighting possible mechanistic targets for further investigation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: